TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04027101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
Study: NCT01932281

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SierraSil
Description: SierraSil is a natural, mineral supplement currently used to improve joint health and function.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic SierraSil 667 mg capsule
Study: NCT03421574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-guided Focused Ultrasound
Description: Focused Ultrasound allows for non-invasive thermal ablation of soft tissue virtually anywhere in the body. Treatment begins by acquiring a series of magnetic resonance (MR) images of the target tissue. The physician then reviews the images on the system workstation, identifies the target, delineates treatment contours, and reviews the treatment plan. Therapy planning software calculates the parameters required to effectively treat (e.g. ablate) the defined region. During treatment, the patient wears a helmet equipped with multiple sources of ultrasound which generate a point of focused energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, causing a thermal coagulation effect.
Study: NCT00879463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion according to the anesthesiologist's judgement
Description: Transfusion if hemoglobin is between 5.5-7 mg/dl
Study: NCT01628419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health intervention
Description: physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.~Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects.
Study: NCT01542229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU)
Description: 12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Treatment as usual (TAU) will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
Study: NCT04597398

Intervention type: DEVICE
Intervention: Evaluation of blood flow with indocyanine green
Study: NCT02870400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: Participants will receive ascending doses of REGN2477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo
Study: NCT00598624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan IV
Description: Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
Study: NCT01297374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activities, dietician counseling and behavioral changes
Description: One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activities, dietician counseling and behavioral changes
Description: One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activities, dietician counseling and behavioral changes
Description: One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes
Study: NCT02751359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: 200, 400, or 800 mg Cannabidiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg Cannabidiol
Study: NCT00885014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Telephone cognitive-behavioral therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EAP
Description: Employees Assistance Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EAP
Description: Employees Assistance Program
Study: NCT03738514

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% fluorocalcium phosphosilicate dentifrice
Description: dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 5% potassium nitrate dentifrice
Description: 5% potassium nitrate dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dentrifice
Description: placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks
Study: NCT01506544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 20mg/kg of Hydroxyurea or the patient's standard daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: 20mg/kg of Hydroxyurea or the patient's standard daily dose
Study: NCT03420365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 30 minutes of either aerobic, or balance and coordination, or reading magazines
Study: NCT01657370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1602
Description: Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1602
Description: Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1602
Description: Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1602
Description: Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1602
Description: Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded.
Study: NCT01127373

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-Beam Intensity-Modulated Radiation Therapy
Description: IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BreastQ questionnaire-
Description: MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
Study: NCT00431704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
Study: NCT01657370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded.
Study: NCT00431704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
Study: NCT02214550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclic microgestin 1/20
Description: Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous microgestin 1/20
Description: Continuous OC use - Pills containing hormones will be taken every day for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous microgestin 1/20
Description: Continuous OC use - Pills containing hormones will be taken every day for 1 year
Study: NCT01382199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Study: NCT02655458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: The following must also be administered before any elotuzumab:~Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po).
Study: NCT02602171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oldenburger sentence test, localization test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oldenburger sentence test, localization test
Study: NCT03277768

Intervention type: DEVICE
Intervention: Resonance Raman Spectroscopy (RRS)
Description: Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 data collection times in infants with and without PDAs.

Intervention type: DEVICE
Intervention: Resonance Raman Spectroscopy (RRS)
Description: Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 data collection times in infants with and without PDAs.
Study: NCT04752124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: High intensity speed based interval treadmill training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional therapy
Description: conventional physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional physical therapy
Study: NCT05336006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training with high protein diet
Description: High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d), as prescribed by a qualified nutritionist.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
Study: NCT02812446

Intervention type: OTHER
Intervention: IAI infection

Intervention type: OTHER
Intervention: Staphylococcus aureus nasal carriage infection
Study: NCT02303171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
Study: NCT01948895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Description: Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
Study: NCT01797991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo for dexamethasone IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo for dexamethasone per os
Study: NCT03177265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging prior to first counseling call
Description: This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-to-Enhance
Description: Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mail Notice
Description: This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
Study: NCT04227392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal radiofrequency
Description: 2 sessions of vaginal radiofrequency therapy with 3 week interval. A session last 20 minutes.
Study: NCT04768699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQG203
Description: TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQG203/NovoSeven®
Description: In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQG203/NovoSeven®
Description: In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQG203
Description: TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
Study: NCT01811901

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduction of DTN
Description: 15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
Study: NCT01216449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Citalopram
Description: Single dose of 20mg parenteral citalopram diluted in 250mL of 0.9% sodium chloride solution, infused over 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
Study: NCT02655458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous PBMC reconstitution
Description: Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASCT
Description: Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are harvested, stored and then returned to the body (engrafted). To be done as part of standard of care.
Study: NCT03135184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HDL Therapeutics PDS-2 System
Description: Delipidation of plasma HDL to reduce coronary atheroma
Study: NCT02218060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography on SOMATOM Force
Description: Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Previous coronary CT angiography on 2nd generation CT scanner
Description: Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
Study: NCT03792204

Intervention type: DIAGNOSTIC_TEST
Intervention: Wearing-off 9 questionnaire
Description: The participants would receive appropriate anti-PD medical treatments according to the patients' need during the investigation.The anti -PD treatment would not be changed in the population of the participants.
Study: NCT01024881

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neutral shoulder position
Description: neutral shoulder position during infraclavicular subclavian catheterization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lowered shoulder position
Description: lowered shoulder position during infraclavicular subclavian catheterization
Study: NCT05952895

Intervention type: PROCEDURE
Intervention: Conventional quadrant-wise scaling and root planing (SRP)
Description: SRP was conducted at baseline, after saliva collection and periodontal assessment, starting with the upper right quadrant and continuing clockwise over four visits at weekly intervals. SRP was performed under local anesthesia by the same periodontist (B.A.) by use of ultrasonic instruments (Mini Piezon, EMS, Nyon, CH) and manual periodontal curettes (Gracey curets, scaler Hu-Friedy, Chicago, IL). All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Self-performed plaque control measures consisted of toothbrushing using the modified Bass technique with a medium toothbrush and a regular toothpaste with fluoride twice a day and interdental cleaning using dental floss and/or interdental brushes once a day.